Skip to content

Heated High Flow Oxygen Use in Infants With Bronchiolitis and Hypoxia

Comparison of Heated Humidified High-flow Nasal Cannula (HHFNC) Versus Standard Nasal Cannula Oxygen Delivery on Respiratory Distress and Length of Stay in Infants With Bronchiolitis and Hypoxia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01662544
Acronym
HHFNC
Enrollment
56
Registered
2012-08-10
Start date
2012-08-31
Completion date
2017-12-31
Last updated
2017-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiolitis, Hypoxia

Keywords

Infants, Bronchiolitis, Hypoxia, Emergency Department, Length of Stay, Pediatrics

Brief summary

Bronchiolitis is a common cold weather seasonal respiratory illness affecting infants and children. Multiple supportive therapies have been tried in infants with bronchiolitis including albuterol, racemic epinephrine, hypertonic saline nebulization, but to date supportive therapy with oxygen is the only proven therapy to decrease respiratory distress in infants with bronchiolitis, with hypertonic saline showing a borderline statistically significant improvement. This prospective, randomized study will compare CSS and PEWS scores on infants who receive oxygen by standard flow nasal cannula and to those who receive oxygen via Humidified High-Flow Nasal Cannula (HHFNC). The results will help determine if infants with viral bronchiolitis who receive humidified high flow nasal cannula oxygen therapy have improved Clinical Severity Score (CSS) and Pediatric Early Warning System (PEWS) scores and ultimately decreased lengths of admissions when compared to patients treated with nasal cannula oxygen therapy with/without bronchodilator therapy. Hypothesis Heated Humidified High-flow Nasal Cannula Delivery of Oxygen decreases respiratory distress as measured by pediatric CSS and PEWS when compared with routine nasal cannula oxygen delivery in infants with bronchiolitis.

Interventions

Sponsors

Children's Hospitals and Clinics of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Months to 18 Months
Healthy volunteers
No

Inclusion criteria

1. Are previously healthy infants ages 3 months to 18 months of age 2. Have O2 saturations of \< 92% on room air while awake 3. Have a clinical diagnosis of bronchiolitis 4. Have a CSS score showing moderate distress \>4 5. Have a planned admission to the hospital for either inpatient or observation status 6. Have parental consent to enroll in study

Exclusion criteria

1. Have significant apnea or bradycardia events reported by parent or witnessed in Emergency Department 2. Have prior airway disease diagnosis other than URI within the previous two months 3. Were previously intubated; previously having had airway bronchoscopy or surgery 4. They are ex-preemies, i.e. had an estimated gestational age of \<37 weeks at time of birth 5. Have a diagnosis of lobar consolidation or round pneumonia by Chest x-ray 6. Have pleural disease by chest x-ray 7. Have history of cardiac disease, renal disease, hematologic disease such as sickle cell disease or leukemia, congenital hemoglobinopathies or Congenital Adrenal Hyperplasia 8. Have undergone prior radiation or chemotherapy 9. Have functional or anatomical bowel obstruction as demonstrated by persistent vomiting or tensely distended abdomen 10. Have history of Choanal atresia or cleft palate 11. Have history of neuromuscular disorder, e.g., Spinal muscular atrophy, muscular dystrophies, cerebral palsy or hypotonia 12. Have impending respiratory failure as demonstrated by blood gas with pCO2 of greater than 60 or apnea spells lasting greater than 30 seconds

Design outcomes

Primary

MeasureTime frame
CSS ScoresStudy specific

Secondary

MeasureTime frame
PEWS ScoreStudy specific

Other

MeasureTime frame
Oxygen needsStudy specific

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026